Project Grant R01AR085629
Award Date 9/5/25
Completion Date 8/31/30
Dollars Obligated $747K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This $250,396 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research to identify differences in DNA regulatory elements that control gene expression in skin cells from individuals of different ancestral backgrounds. The research team at the Icahn School of Medicine at Mount Sinai will utilize advanced genomic techniques, including...
- This Project Grant award, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to define and treat genetic abnormalities in overlapping rashes of psoriasis and atopic dermatitis (termed "PSO-AD"). The $628,968 award to the University of California, San Francisco will leverage innovative biomarker techniques, including spatial transcriptomics and...
- This $858,186 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports a research project titled "Decoding T Cell Clonotypes, Biology and Predictive Biomarkers Associated with Immune Checkpoint Myocarditis." The project aims to investigate the mechanisms underlying immune-related myocarditis, a potentially fatal adverse event associated with immune checkpoint inhibitor cancer therapies. Using...
- The $735,372 federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research Program (CFDA 93.846) supports research to identify the key transcription factors and cytokine signals that regulate the expression of inflammatory chemokine receptors on T cells in chronic autoimmune conditions. The goal is to elucidate the dominant pathways controlling coordinated T cell migration to...
- This federal Project Grant award, valued at $1,826,181.00 and effective from September 1, 2025 to August 31, 2028, was issued by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research grant program (CFDA 93.846). The grant aims to comprehensively understand the contribution of Langerhans cells, resident cells in the epidermis, to chronic itch associated with various skin and systemic diseases. The research...
- This federal Project Grant award of $102,341 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research at Stanford University to characterize the role of RNA-binding protein assemblies in epidermal homeostasis. The research aims to better understand how these protein complexes regulate keratinocyte proliferation and differentiation, which is critical for...
- This $462,092 Cooperative Agreement award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) is focused on investigating novel immune checkpoint targets for the topical immunoprevention of keratinocytic skin cancer. The award is held by the University of Arizona and will run from August 1, 2025 to July 31, 2027. The key objectives of the project are to 1) use human samples to identify novel immune checkpoint proteins that are upregulated early in the skin...
- The National Cancer Institute (NCI) awarded a $547,945 Project Grant under CFDA 93.396 (Cancer Biology Research) to The Johns Hopkins University to conduct research on the pathogenesis of immune checkpoint inhibitor-induced myocarditis. The project aims to investigate how biological factors such as prior cardiac injury, age, and sex modulate the risk of this adverse event, which occurs in 1-2% of cancer patients receiving immune checkpoint inhibitor therapy but can be fatal in up to 50% of...
- This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846) provides $249,000.00 to the University of Massachusetts Medical School to develop a therapeutic platform using small interfering RNA (siRNA) for gene silencing in the treatment of skin diseases. The project aims to evaluate the safety and efficacy of silencing the JAK1 immune mediator in...
- This $375,100 federal Project Grant award was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant funds a study to investigate the interplay between nucleic-acid-dependent phase separation and immune responses against cyclic GMP-AMP synthase (cGAS) in systemic lupus erythematosus (SLE). The research aims to determine how changes in the biophysical...